Amgen (NSDQ:AMGN) announced today that it inked a one-year collaboration with Boston Children’s Hospital to study patients with pain syndromes in an effort to identify potential genetic targets.
The collaboration will combine Amgen’s work in genetic target identification and the division of pain medicine at Boston Children’s Hospital.
Get the full story at our sister site, Drug Delivery Business News.
The post Amgen, Boston Children’s Hospital partner to find genes linked to pain disorders appeared first on MassDevice.